ClinicalTrials.gg

Program

visugromab

Also written as “Visugromab (CTL-002)”, “Visugromab RDE (recommended dose for expansion)” and “Visugromab 6mg/kg”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Cachexia · Urinary Bladder Neoplasms, led by CatalYm.

Furthest: phase 3, since Jul 31, 20256 company-led studies, 5 open or runningNext primary completion: Apr 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CatalYm65 open or runningphase 3since Jul 31, 2025Jan 14, 2021Apr 30, 2028phase 2 · NCT04725474

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 14, 2021First study: phase 2 study in Solid Tumor, AdultFirst studyNCT04725474 · 199 enrolled · Germany, Spain, Switzerland
  2. Aug 23, 2023Phase 2 study in Urinary Bladder NeoplasmsNCT06059547 · 31 enrolled · Italy
  3. Jul 10, 2025Phase 2 study in Metastatic Non-Squamous Non-Small Cell Lung CancerNCT07098988 · 107 planned · United States, Germany, Italy and more
  4. Jul 31, 2025Phase 3 study in CachexiaNCT07112196 · 518 planned · United States, Bulgaria, Czechia and more
  5. Oct 20, 2025Phase 2 study in Carcinoma, HepatocellularNCT07219459 · 104 planned · United States, France, Germany and more
  6. Nov 19, 2025Phase 2 study in Metastatic Non-Squamous Non-Small Cell Lung CancerNCT07246863 · 131 planned · United States, Germany, Italy and more

Ahead

  1. Apr 30, 2028Primary completion: phase 2 study in Solid Tumor, AdultNCT04725474
  2. Mar 31, 2029Primary completion: phase 2 study in Metastatic Non-Squamous Non-Small Cell Lung CancerNCT07098988
  3. Sep 2029Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07219459
  4. Oct 1, 2029Primary completion: phase 2 study in Metastatic Non-Squamous Non-Small Cell Lung CancerNCT07246863

TargetBeta

GDF15 →PDF →read by rule
“A humanized, hinge-stabilized immunoglobulin G4 (IgG4) monoclonal antibody directed against growth/differentiation factor 15 (GDF-15; macrophage inhibitory cytokine-1; MIC-1; non-steroidal anti-inflammatory drug-inducible gene-1; NAG-1; placental transforming growth factor-beta; pTGFB; prostate-deri”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
rilogrotugruleLG Chemphase 33

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07246863Metastatic Non-Squamous Non-Small Cell Lung Cancer · United States, Germany, Italy and more2RecruitingOct 1, 2029131
NCT07219459Carcinoma, Hepatocellular · United States, France, Germany and more2RecruitingSep 2029104
NCT07112196Cachexia · United States, Bulgaria, Czechia and more3RecruitingDec 2029518
NCT07098988Metastatic Non-Squamous Non-Small Cell Lung Cancer · United States, Germany, Italy and more2RecruitingMar 31, 2029107
NCT06059547Urinary Bladder Neoplasms · Italy2CompletedOct 16, 202531
NCT04725474Solid Tumor, Adult · Germany, Spain, Switzerland2Active, not recruitingApr 30, 2028199

How it is read

Names in the registry

  • “Visugromab (CTL-002)”, 4 entries
  • “Visugromab RDE (recommended dose for expansion)”, 1 entry
  • “Visugromab 6mg/kg”, 1 entry
  • “Visugromab”, 1 entry
  • “visugromab (CTL-002)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.